Clinical Evaluation of Cefotiam Hexetil in Chronic Respiratory Tract Infections —Double-blind controlled trial using cefaclor as a positive control—

Atsushi Saito; Yoshiteru Shigeno; Yuei Irabu; Yoshikazu Kawakami; Shosaku Abe; Tsuguo Terai; Takashi Yoshikawa; Tatsuo Nagai; Hidekazu Inaba; Akira Saito; Masumi Tomizawa; Ichiro Nakayama; Osamu Yajima; Yohmei Hiraga; Mitsuhide Ohmichi; Susumu Ito; Akiji Kasagi; Kazuo Takebe; Takeshi Osonoi; Masato Hayashi; Jun Hori; Kenjiro Akai; Masahiro Yaekashiwa; Toru Takijima; Yasuo Tanno; Kiyoshi Konno; Kotaro Oizumi; Akira Watanabe; Seiichi Aonuma; Hiroyuki Nakai; Junichi Saito; Teruo Hasuike; Izumi Hayashi; Masataka Katsu; Shinji Okui; Toshio Fukui; Satoki Honma; Satoshi Kitamura; Ryokuro Matsuoka; Kaoru Shimada; Yasuyuki Sano; Yasufumi Miyamoto; Koh Nakata; Jingoro Shimada; Kohya Shiba; Hiroyuki Kobayashi; Hiroshi Oshitani; Keimei Mashimo; Yoshiji Yamane; Masakazu Kato; Takao Tashiro; Hiroichi Tanimoto; Koichiro Nakata; Yoshitaka Nakamori; Naohiko Chonabayashi; Kentaro Watanabe; Masaru Koyama; Shoichiro Irimajiri; Yasuo Matsuoka; Yasuhisa Kitagawa; Ippei Fujimori; Yoshio Kobayashi; Takao Okubo; Akira Ito; Hirotada Ikeda; Shigeki Odagiri; Kaneo Suzuki; Kou Murohashi; Masaaki Arakawa; Kouichi Wada; Osamu Sekine; Nobuki Aoki; Kaoru Oyama; Toshiyuki Yamamoto; Kanzo Suzuki; Kazuhide Yamamoto; Toshihiko Takeuchi; Masahito Kato; Joichi Kato; Yasuo Yamada; Hidekazu Hanaki; Go Ito; Fumiyuki Kuse; Takako Murayama; Naoshi Nishimura; Shunsaku Oshima; Takateru Izumi; Kohichi Nishimura; Shinichiro Heki; Naoki Fujimura; Hitoshi Asamoto; Sadao Ikeda; Michio Nakajima; Fumio Miki; Hisao Takahashi; Tadao Ochi; Norio Itakura; Takashi Osugi; Nobuhiro Narita; Masayoshi Sawaki; Keiichi Mikasa; Rinzo Soejima; Yoshihito Niki; Takao Sasaki; Yukio Matsumoto; Yuji Sugimoto; Yoshiro Sawae; Toshiyuki Ishimaru; Koji Takagi; Takayoshi Yamane; Kazuhiro Hayashida; Yukio Kumagaya; Michio Fukuma; Hiroshi Murata; Hideyuki Gondo; Masahide Takii; Masaru Nasu; Hideaki Shigeno; Jun Goto; Takayoshi Tashiro; Kohei Hara; Shigeru Kohno; Toshiaki Hayashi; Mitsuo Kaku; Kazuo Sasayama; Akira Yasuoka; Kinichi Izumikawa; Kohichi Watanabe; Kazuhiro Okuno; Kohta Kohno; Naomi Ito; Hiromaru Iwasaki; Hiroshige Oda; Keizo Matsumoto; Tsuyoshi Nagatake; Toshiaki Yoshida; Masayuki Ando; Moritaka Suga; Keizo Yamaguchi; Kazuyuki Sugawara; Nobuya Ggawa

doi:10.11250/chemotherapy1953.37.455

Clinical Evaluation of Cefotiam Hexetil in Chronic Respiratory Tract Infections —Double-blind controlled trial using cefaclor as a positive control—

Atsushi Saito, Yoshiteru Shigeno, Yuei Irabu, Yoshikazu Kawakami, Shosaku Abe, Tsuguo Terai, Takashi Yoshikawa, Tatsuo Nagai, Hidekazu Inaba, Akira Saito, Masumi Tomizawa, Ichiro Nakayama, Osamu Yajima, Yohmei Hiraga, Mitsuhide Ohmichi, Susumu Ito, Akiji Kasagi, Kazuo Takebe, Takeshi Osonoi, Masato HayashiJun Hori, Kenjiro Akai, Masahiro Yaekashiwa, Toru Takijima, Yasuo Tanno, Kiyoshi Konno, Kotaro Oizumi, Akira Watanabe, Seiichi Aonuma, Hiroyuki Nakai, Junichi Saito, Teruo Hasuike, Izumi Hayashi, Masataka Katsu, Shinji Okui, Toshio Fukui, Satoki Honma, Satoshi Kitamura, Ryokuro Matsuoka, Kaoru Shimada, Yasuyuki Sano, Yasufumi Miyamoto, Koh Nakata, Jingoro Shimada, Kohya Shiba, Hiroyuki Kobayashi, Hiroshi Oshitani, Keimei Mashimo, Yoshiji Yamane, Masakazu Kato, Takao Tashiro, Hiroichi Tanimoto, Koichiro Nakata, Yoshitaka Nakamori, Naohiko Chonabayashi, Kentaro Watanabe, Masaru Koyama, Shoichiro Irimajiri, Yasuo Matsuoka, Yasuhisa Kitagawa, Ippei Fujimori, Yoshio Kobayashi, Takao Okubo, Akira Ito, Hirotada Ikeda, Shigeki Odagiri, Kaneo Suzuki, Kou Murohashi, Masaaki Arakawa, Kouichi Wada, Osamu Sekine, Nobuki Aoki, Kaoru Oyama, Toshiyuki Yamamoto, Kanzo Suzuki, Kazuhide Yamamoto, Toshihiko Takeuchi, Masahito Kato, Joichi Kato, Yasuo Yamada, Hidekazu Hanaki, Go Ito, Fumiyuki Kuse, Takako Murayama, Naoshi Nishimura, Shunsaku Oshima, Takateru Izumi, Kohichi Nishimura, Shinichiro Heki, Naoki Fujimura, Hitoshi Asamoto, Sadao Ikeda, Michio Nakajima, Fumio Miki, Hisao Takahashi, Tadao Ochi, Norio Itakura, Takashi Osugi, Nobuhiro Narita, Masayoshi Sawaki, Keiichi Mikasa, Rinzo Soejima, Yoshihito Niki, Takao Sasaki, Yukio Matsumoto, Yuji Sugimoto, Yoshiro Sawae, Toshiyuki Ishimaru, Koji Takagi, Takayoshi Yamane, Kazuhiro Hayashida, Yukio Kumagaya, Michio Fukuma, Hiroshi Murata, Hideyuki Gondo, Masahide Takii, Masaru Nasu, Hideaki Shigeno, Jun Goto, Takayoshi Tashiro, Kohei Hara, Shigeru Kohno, Toshiaki Hayashi, Mitsuo Kaku, Kazuo Sasayama, Akira Yasuoka, Kinichi Izumikawa, Kohichi Watanabe, Kazuhiro Okuno, Kohta Kohno, Naomi Ito, Hiromaru Iwasaki, Hiroshige Oda, Keizo Matsumoto, Tsuyoshi Nagatake, Toshiaki Yoshida, Masayuki Ando, Moritaka Suga, Keizo Yamaguchi, Kazuyuki Sugawara, Nobuya Ggawa

MED - Medical Sciences

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

Using the double-blind method, we evaluated the efficacy, safety and usefulness of cefotiam hexetil (CTM-HE) for the treatment of chronic respiratory tract infections using cefaclor (CCL) as control drug. The results obtained were as follows: Patients were given orally, in 3 divided doses, CTM-HE in a daily dose of 1200mg (as cefotiam) or CCL in a daily dose of 1500 mg for 14 consecutive days as a rule. 1) Clinical response was judged by the committee as good and excellent in 67. 3%(76/113) of thepatients on CTM-HE treatment and 65.2%(73/112) of those on CCL treatment, and by the attending physicians in 67.0%(75/112) of those on CTM-HE and 59. 8%(67/112) of those on CCL. 2) Bacteriological response by causative organisms was judged as eradicated in 64.0%(48/75) in the CTM-HE treatment group and 55.8%(43/77) in the CCL treatment group. 3) As for the safety evaluation, adverse reactions were reported in 7.6%(9/119) of the patients on CTM-HE and 8.8%(11/125) of those on CCL. Abnormal alterations of laboratory findings occured in 21.4%(24/112) of the patients on CTM-HE and 13.3%(15/113) of those on CCL. Major adverse reactions to both treatments included gastrointestinal disorders such as diarrhea. Most of the abnormal laboratory findings were increase in eosinophils and in serum transaminases, which did not particularly differ from those observed with conventionally available cephem antibiotics. 4) As to utility, the drug was judged as fairly useful and better by the committee in 66.4%(75/113) of the patients on CTM-HE and 62.6%(72/115) of those on CCL, and by the attending physicians in 65.2%(73/112) of those on CTM-HE and 59.1%(68/115) of those on CCL. The above results indicate that the daily dose of 1200 mg of CTM-HE is comparable to 1500 mg of CCL in efficacy and safety, and we conclude that CTM-HE is useful for the treatment of chronic respiratory tract infections.

Original language	English
Pages (from-to)	455-481
Number of pages	27
Journal	Chemotherapy
Volume	37
Issue number	4
DOIs	https://doi.org/10.11250/chemotherapy1953.37.455
Publication status	Published - 1989

ASJC Scopus subject areas

Pharmacology (medical)
Infectious Diseases
Pharmacology
Drug Discovery
Oncology

Access to Document

10.11250/chemotherapy1953.37.455

Fingerprint Dive into the research topics of 'Clinical Evaluation of Cefotiam Hexetil in Chronic Respiratory Tract Infections —Double-blind controlled trial using cefaclor as a positive control—'. Together they form a unique fingerprint.

Cite this

Saito, A., Shigeno, Y., Irabu, Y., Kawakami, Y., Abe, S., Terai, T., Yoshikawa, T., Nagai, T., Inaba, H., Saito, A., Tomizawa, M., Nakayama, I., Yajima, O., Hiraga, Y., Ohmichi, M., Ito, S., Kasagi, A., Takebe, K., Osonoi, T., ... Ggawa, N. (1989). Clinical Evaluation of Cefotiam Hexetil in Chronic Respiratory Tract Infections —Double-blind controlled trial using cefaclor as a positive control—. Chemotherapy, 37(4), 455-481. https://doi.org/10.11250/chemotherapy1953.37.455

Clinical Evaluation of Cefotiam Hexetil in Chronic Respiratory Tract Infections —Double-blind controlled trial using cefaclor as a positive control—. / Saito, Atsushi; Shigeno, Yoshiteru; Irabu, Yuei; Kawakami, Yoshikazu; Abe, Shosaku; Terai, Tsuguo; Yoshikawa, Takashi; Nagai, Tatsuo; Inaba, Hidekazu; Saito, Akira; Tomizawa, Masumi; Nakayama, Ichiro; Yajima, Osamu; Hiraga, Yohmei; Ohmichi, Mitsuhide; Ito, Susumu; Kasagi, Akiji; Takebe, Kazuo; Osonoi, Takeshi; Hayashi, Masato; Hori, Jun; Akai, Kenjiro; Yaekashiwa, Masahiro; Takijima, Toru; Tanno, Yasuo; Konno, Kiyoshi; Oizumi, Kotaro; Watanabe, Akira; Aonuma, Seiichi; Nakai, Hiroyuki; Saito, Junichi; Hasuike, Teruo; Hayashi, Izumi; Katsu, Masataka; Okui, Shinji; Fukui, Toshio; Honma, Satoki; Kitamura, Satoshi; Matsuoka, Ryokuro; Shimada, Kaoru; Sano, Yasuyuki; Miyamoto, Yasufumi; Nakata, Koh; Shimada, Jingoro; Shiba, Kohya; Kobayashi, Hiroyuki; Oshitani, Hiroshi; Mashimo, Keimei; Yamane, Yoshiji; Kato, Masakazu; Tashiro, Takao; Tanimoto, Hiroichi; Nakata, Koichiro; Nakamori, Yoshitaka; Chonabayashi, Naohiko; Watanabe, Kentaro; Koyama, Masaru; Irimajiri, Shoichiro; Matsuoka, Yasuo; Kitagawa, Yasuhisa; Fujimori, Ippei; Kobayashi, Yoshio; Okubo, Takao; Ito, Akira; Ikeda, Hirotada; Odagiri, Shigeki; Suzuki, Kaneo; Murohashi, Kou; Arakawa, Masaaki; Wada, Kouichi; Sekine, Osamu; Aoki, Nobuki; Oyama, Kaoru; Yamamoto, Toshiyuki; Suzuki, Kanzo; Yamamoto, Kazuhide; Takeuchi, Toshihiko; Kato, Masahito; Kato, Joichi; Yamada, Yasuo; Hanaki, Hidekazu; Ito, Go; Kuse, Fumiyuki; Murayama, Takako; Nishimura, Naoshi; Oshima, Shunsaku; Izumi, Takateru; Nishimura, Kohichi; Heki, Shinichiro; Fujimura, Naoki; Asamoto, Hitoshi; Ikeda, Sadao; Nakajima, Michio; Miki, Fumio; Takahashi, Hisao; Ochi, Tadao; Itakura, Norio; Osugi, Takashi; Narita, Nobuhiro; Sawaki, Masayoshi; Mikasa, Keiichi; Soejima, Rinzo; Niki, Yoshihito; Sasaki, Takao; Matsumoto, Yukio; Sugimoto, Yuji; Sawae, Yoshiro; Ishimaru, Toshiyuki; Takagi, Koji; Yamane, Takayoshi; Hayashida, Kazuhiro; Kumagaya, Yukio; Fukuma, Michio; Murata, Hiroshi; Gondo, Hideyuki; Takii, Masahide; Nasu, Masaru; Shigeno, Hideaki; Goto, Jun; Tashiro, Takayoshi; Hara, Kohei; Kohno, Shigeru; Hayashi, Toshiaki; Kaku, Mitsuo; Sasayama, Kazuo; Yasuoka, Akira; Izumikawa, Kinichi; Watanabe, Kohichi; Okuno, Kazuhiro; Kohno, Kohta; Ito, Naomi; Iwasaki, Hiromaru; Oda, Hiroshige; Matsumoto, Keizo; Nagatake, Tsuyoshi; Yoshida, Toshiaki; Ando, Masayuki; Suga, Moritaka; Yamaguchi, Keizo; Sugawara, Kazuyuki; Ggawa, Nobuya.

In: Chemotherapy, Vol. 37, No. 4, 1989, p. 455-481.

Research output: Contribution to journal › Article › peer-review

Saito, A, Shigeno, Y, Irabu, Y, Kawakami, Y, Abe, S, Terai, T, Yoshikawa, T, Nagai, T, Inaba, H, Saito, A, Tomizawa, M, Nakayama, I, Yajima, O, Hiraga, Y, Ohmichi, M, Ito, S, Kasagi, A, Takebe, K, Osonoi, T, Hayashi, M, Hori, J, Akai, K, Yaekashiwa, M, Takijima, T, Tanno, Y, Konno, K, Oizumi, K, Watanabe, A, Aonuma, S, Nakai, H, Saito, J, Hasuike, T, Hayashi, I, Katsu, M, Okui, S, Fukui, T, Honma, S, Kitamura, S, Matsuoka, R, Shimada, K, Sano, Y, Miyamoto, Y, Nakata, K, Shimada, J, Shiba, K, Kobayashi, H, Oshitani, H, Mashimo, K, Yamane, Y, Kato, M, Tashiro, T, Tanimoto, H, Nakata, K, Nakamori, Y, Chonabayashi, N, Watanabe, K, Koyama, M, Irimajiri, S, Matsuoka, Y, Kitagawa, Y, Fujimori, I, Kobayashi, Y, Okubo, T, Ito, A, Ikeda, H, Odagiri, S, Suzuki, K, Murohashi, K, Arakawa, M, Wada, K, Sekine, O, Aoki, N, Oyama, K, Yamamoto, T, Suzuki, K, Yamamoto, K, Takeuchi, T, Kato, M, Kato, J, Yamada, Y, Hanaki, H, Ito, G, Kuse, F, Murayama, T, Nishimura, N, Oshima, S, Izumi, T, Nishimura, K, Heki, S, Fujimura, N, Asamoto, H, Ikeda, S, Nakajima, M, Miki, F, Takahashi, H, Ochi, T, Itakura, N, Osugi, T, Narita, N, Sawaki, M, Mikasa, K, Soejima, R, Niki, Y, Sasaki, T, Matsumoto, Y, Sugimoto, Y, Sawae, Y, Ishimaru, T, Takagi, K, Yamane, T, Hayashida, K, Kumagaya, Y, Fukuma, M, Murata, H, Gondo, H, Takii, M, Nasu, M, Shigeno, H, Goto, J, Tashiro, T, Hara, K, Kohno, S, Hayashi, T, Kaku, M, Sasayama, K, Yasuoka, A, Izumikawa, K, Watanabe, K, Okuno, K, Kohno, K, Ito, N, Iwasaki, H, Oda, H, Matsumoto, K, Nagatake, T, Yoshida, T, Ando, M, Suga, M, Yamaguchi, K, Sugawara, K & Ggawa, N 1989, 'Clinical Evaluation of Cefotiam Hexetil in Chronic Respiratory Tract Infections —Double-blind controlled trial using cefaclor as a positive control—', Chemotherapy, vol. 37, no. 4, pp. 455-481. https://doi.org/10.11250/chemotherapy1953.37.455

Saito, Atsushi ; Shigeno, Yoshiteru ; Irabu, Yuei ; Kawakami, Yoshikazu ; Abe, Shosaku ; Terai, Tsuguo ; Yoshikawa, Takashi ; Nagai, Tatsuo ; Inaba, Hidekazu ; Saito, Akira ; Tomizawa, Masumi ; Nakayama, Ichiro ; Yajima, Osamu ; Hiraga, Yohmei ; Ohmichi, Mitsuhide ; Ito, Susumu ; Kasagi, Akiji ; Takebe, Kazuo ; Osonoi, Takeshi ; Hayashi, Masato ; Hori, Jun ; Akai, Kenjiro ; Yaekashiwa, Masahiro ; Takijima, Toru ; Tanno, Yasuo ; Konno, Kiyoshi ; Oizumi, Kotaro ; Watanabe, Akira ; Aonuma, Seiichi ; Nakai, Hiroyuki ; Saito, Junichi ; Hasuike, Teruo ; Hayashi, Izumi ; Katsu, Masataka ; Okui, Shinji ; Fukui, Toshio ; Honma, Satoki ; Kitamura, Satoshi ; Matsuoka, Ryokuro ; Shimada, Kaoru ; Sano, Yasuyuki ; Miyamoto, Yasufumi ; Nakata, Koh ; Shimada, Jingoro ; Shiba, Kohya ; Kobayashi, Hiroyuki ; Oshitani, Hiroshi ; Mashimo, Keimei ; Yamane, Yoshiji ; Kato, Masakazu ; Tashiro, Takao ; Tanimoto, Hiroichi ; Nakata, Koichiro ; Nakamori, Yoshitaka ; Chonabayashi, Naohiko ; Watanabe, Kentaro ; Koyama, Masaru ; Irimajiri, Shoichiro ; Matsuoka, Yasuo ; Kitagawa, Yasuhisa ; Fujimori, Ippei ; Kobayashi, Yoshio ; Okubo, Takao ; Ito, Akira ; Ikeda, Hirotada ; Odagiri, Shigeki ; Suzuki, Kaneo ; Murohashi, Kou ; Arakawa, Masaaki ; Wada, Kouichi ; Sekine, Osamu ; Aoki, Nobuki ; Oyama, Kaoru ; Yamamoto, Toshiyuki ; Suzuki, Kanzo ; Yamamoto, Kazuhide ; Takeuchi, Toshihiko ; Kato, Masahito ; Kato, Joichi ; Yamada, Yasuo ; Hanaki, Hidekazu ; Ito, Go ; Kuse, Fumiyuki ; Murayama, Takako ; Nishimura, Naoshi ; Oshima, Shunsaku ; Izumi, Takateru ; Nishimura, Kohichi ; Heki, Shinichiro ; Fujimura, Naoki ; Asamoto, Hitoshi ; Ikeda, Sadao ; Nakajima, Michio ; Miki, Fumio ; Takahashi, Hisao ; Ochi, Tadao ; Itakura, Norio ; Osugi, Takashi ; Narita, Nobuhiro ; Sawaki, Masayoshi ; Mikasa, Keiichi ; Soejima, Rinzo ; Niki, Yoshihito ; Sasaki, Takao ; Matsumoto, Yukio ; Sugimoto, Yuji ; Sawae, Yoshiro ; Ishimaru, Toshiyuki ; Takagi, Koji ; Yamane, Takayoshi ; Hayashida, Kazuhiro ; Kumagaya, Yukio ; Fukuma, Michio ; Murata, Hiroshi ; Gondo, Hideyuki ; Takii, Masahide ; Nasu, Masaru ; Shigeno, Hideaki ; Goto, Jun ; Tashiro, Takayoshi ; Hara, Kohei ; Kohno, Shigeru ; Hayashi, Toshiaki ; Kaku, Mitsuo ; Sasayama, Kazuo ; Yasuoka, Akira ; Izumikawa, Kinichi ; Watanabe, Kohichi ; Okuno, Kazuhiro ; Kohno, Kohta ; Ito, Naomi ; Iwasaki, Hiromaru ; Oda, Hiroshige ; Matsumoto, Keizo ; Nagatake, Tsuyoshi ; Yoshida, Toshiaki ; Ando, Masayuki ; Suga, Moritaka ; Yamaguchi, Keizo ; Sugawara, Kazuyuki ; Ggawa, Nobuya. / Clinical Evaluation of Cefotiam Hexetil in Chronic Respiratory Tract Infections —Double-blind controlled trial using cefaclor as a positive control—. In: Chemotherapy. 1989 ; Vol. 37, No. 4. pp. 455-481.

@article{6b2d1210ca9c417ea0f610cbfbe5b2da,

title = "Clinical Evaluation of Cefotiam Hexetil in Chronic Respiratory Tract Infections —Double-blind controlled trial using cefaclor as a positive control—",

abstract = "Using the double-blind method, we evaluated the efficacy, safety and usefulness of cefotiam hexetil (CTM-HE) for the treatment of chronic respiratory tract infections using cefaclor (CCL) as control drug. The results obtained were as follows: Patients were given orally, in 3 divided doses, CTM-HE in a daily dose of 1200mg (as cefotiam) or CCL in a daily dose of 1500 mg for 14 consecutive days as a rule. 1) Clinical response was judged by the committee as good and excellent in 67. 3%(76/113) of thepatients on CTM-HE treatment and 65.2%(73/112) of those on CCL treatment, and by the attending physicians in 67.0%(75/112) of those on CTM-HE and 59. 8%(67/112) of those on CCL. 2) Bacteriological response by causative organisms was judged as eradicated in 64.0%(48/75) in the CTM-HE treatment group and 55.8%(43/77) in the CCL treatment group. 3) As for the safety evaluation, adverse reactions were reported in 7.6%(9/119) of the patients on CTM-HE and 8.8%(11/125) of those on CCL. Abnormal alterations of laboratory findings occured in 21.4%(24/112) of the patients on CTM-HE and 13.3%(15/113) of those on CCL. Major adverse reactions to both treatments included gastrointestinal disorders such as diarrhea. Most of the abnormal laboratory findings were increase in eosinophils and in serum transaminases, which did not particularly differ from those observed with conventionally available cephem antibiotics. 4) As to utility, the drug was judged as fairly useful and better by the committee in 66.4%(75/113) of the patients on CTM-HE and 62.6%(72/115) of those on CCL, and by the attending physicians in 65.2%(73/112) of those on CTM-HE and 59.1%(68/115) of those on CCL. The above results indicate that the daily dose of 1200 mg of CTM-HE is comparable to 1500 mg of CCL in efficacy and safety, and we conclude that CTM-HE is useful for the treatment of chronic respiratory tract infections.",

author = "Atsushi Saito and Yoshiteru Shigeno and Yuei Irabu and Yoshikazu Kawakami and Shosaku Abe and Tsuguo Terai and Takashi Yoshikawa and Tatsuo Nagai and Hidekazu Inaba and Akira Saito and Masumi Tomizawa and Ichiro Nakayama and Osamu Yajima and Yohmei Hiraga and Mitsuhide Ohmichi and Susumu Ito and Akiji Kasagi and Kazuo Takebe and Takeshi Osonoi and Masato Hayashi and Jun Hori and Kenjiro Akai and Masahiro Yaekashiwa and Toru Takijima and Yasuo Tanno and Kiyoshi Konno and Kotaro Oizumi and Akira Watanabe and Seiichi Aonuma and Hiroyuki Nakai and Junichi Saito and Teruo Hasuike and Izumi Hayashi and Masataka Katsu and Shinji Okui and Toshio Fukui and Satoki Honma and Satoshi Kitamura and Ryokuro Matsuoka and Kaoru Shimada and Yasuyuki Sano and Yasufumi Miyamoto and Koh Nakata and Jingoro Shimada and Kohya Shiba and Hiroyuki Kobayashi and Hiroshi Oshitani and Keimei Mashimo and Yoshiji Yamane and Masakazu Kato and Takao Tashiro and Hiroichi Tanimoto and Koichiro Nakata and Yoshitaka Nakamori and Naohiko Chonabayashi and Kentaro Watanabe and Masaru Koyama and Shoichiro Irimajiri and Yasuo Matsuoka and Yasuhisa Kitagawa and Ippei Fujimori and Yoshio Kobayashi and Takao Okubo and Akira Ito and Hirotada Ikeda and Shigeki Odagiri and Kaneo Suzuki and Kou Murohashi and Masaaki Arakawa and Kouichi Wada and Osamu Sekine and Nobuki Aoki and Kaoru Oyama and Toshiyuki Yamamoto and Kanzo Suzuki and Kazuhide Yamamoto and Toshihiko Takeuchi and Masahito Kato and Joichi Kato and Yasuo Yamada and Hidekazu Hanaki and Go Ito and Fumiyuki Kuse and Takako Murayama and Naoshi Nishimura and Shunsaku Oshima and Takateru Izumi and Kohichi Nishimura and Shinichiro Heki and Naoki Fujimura and Hitoshi Asamoto and Sadao Ikeda and Michio Nakajima and Fumio Miki and Hisao Takahashi and Tadao Ochi and Norio Itakura and Takashi Osugi and Nobuhiro Narita and Masayoshi Sawaki and Keiichi Mikasa and Rinzo Soejima and Yoshihito Niki and Takao Sasaki and Yukio Matsumoto and Yuji Sugimoto and Yoshiro Sawae and Toshiyuki Ishimaru and Koji Takagi and Takayoshi Yamane and Kazuhiro Hayashida and Yukio Kumagaya and Michio Fukuma and Hiroshi Murata and Hideyuki Gondo and Masahide Takii and Masaru Nasu and Hideaki Shigeno and Jun Goto and Takayoshi Tashiro and Kohei Hara and Shigeru Kohno and Toshiaki Hayashi and Mitsuo Kaku and Kazuo Sasayama and Akira Yasuoka and Kinichi Izumikawa and Kohichi Watanabe and Kazuhiro Okuno and Kohta Kohno and Naomi Ito and Hiromaru Iwasaki and Hiroshige Oda and Keizo Matsumoto and Tsuyoshi Nagatake and Toshiaki Yoshida and Masayuki Ando and Moritaka Suga and Keizo Yamaguchi and Kazuyuki Sugawara and Nobuya Ggawa",

year = "1989",

doi = "10.11250/chemotherapy1953.37.455",

language = "English",

volume = "37",

pages = "455--481",

journal = "CHEMOTHERAPY",

issn = "0009-3165",

number = "4",

}

TY - JOUR

T1 - Clinical Evaluation of Cefotiam Hexetil in Chronic Respiratory Tract Infections —Double-blind controlled trial using cefaclor as a positive control—

AU - Saito, Atsushi

AU - Shigeno, Yoshiteru

AU - Irabu, Yuei

AU - Kawakami, Yoshikazu

AU - Abe, Shosaku

AU - Terai, Tsuguo

AU - Yoshikawa, Takashi

AU - Nagai, Tatsuo

AU - Inaba, Hidekazu

AU - Saito, Akira

AU - Tomizawa, Masumi

AU - Nakayama, Ichiro

AU - Yajima, Osamu

AU - Hiraga, Yohmei

AU - Ohmichi, Mitsuhide

AU - Ito, Susumu

AU - Kasagi, Akiji

AU - Takebe, Kazuo

AU - Osonoi, Takeshi

AU - Hayashi, Masato

AU - Hori, Jun

AU - Akai, Kenjiro

AU - Yaekashiwa, Masahiro

AU - Takijima, Toru

AU - Tanno, Yasuo

AU - Konno, Kiyoshi

AU - Oizumi, Kotaro

AU - Watanabe, Akira

AU - Aonuma, Seiichi

AU - Nakai, Hiroyuki

AU - Saito, Junichi

AU - Hasuike, Teruo

AU - Hayashi, Izumi

AU - Katsu, Masataka

AU - Okui, Shinji

AU - Fukui, Toshio

AU - Honma, Satoki

AU - Kitamura, Satoshi

AU - Matsuoka, Ryokuro

AU - Shimada, Kaoru

AU - Sano, Yasuyuki

AU - Miyamoto, Yasufumi

AU - Nakata, Koh

AU - Shimada, Jingoro

AU - Shiba, Kohya

AU - Kobayashi, Hiroyuki

AU - Oshitani, Hiroshi

AU - Mashimo, Keimei

AU - Yamane, Yoshiji

AU - Kato, Masakazu

AU - Tashiro, Takao

AU - Tanimoto, Hiroichi

AU - Nakata, Koichiro

AU - Nakamori, Yoshitaka

AU - Chonabayashi, Naohiko

AU - Watanabe, Kentaro

AU - Koyama, Masaru

AU - Irimajiri, Shoichiro

AU - Matsuoka, Yasuo

AU - Kitagawa, Yasuhisa

AU - Fujimori, Ippei

AU - Kobayashi, Yoshio

AU - Okubo, Takao

AU - Ito, Akira

AU - Ikeda, Hirotada

AU - Odagiri, Shigeki

AU - Suzuki, Kaneo

AU - Murohashi, Kou

AU - Arakawa, Masaaki

AU - Wada, Kouichi

AU - Sekine, Osamu

AU - Aoki, Nobuki

AU - Oyama, Kaoru

AU - Yamamoto, Toshiyuki

AU - Suzuki, Kanzo

AU - Yamamoto, Kazuhide

AU - Takeuchi, Toshihiko

AU - Kato, Masahito

AU - Kato, Joichi

AU - Yamada, Yasuo

AU - Hanaki, Hidekazu

AU - Ito, Go

AU - Kuse, Fumiyuki

AU - Murayama, Takako

AU - Nishimura, Naoshi

AU - Oshima, Shunsaku

AU - Izumi, Takateru

AU - Nishimura, Kohichi

AU - Heki, Shinichiro

AU - Fujimura, Naoki

AU - Asamoto, Hitoshi

AU - Ikeda, Sadao

AU - Nakajima, Michio

AU - Miki, Fumio

AU - Takahashi, Hisao

AU - Ochi, Tadao

AU - Itakura, Norio

AU - Osugi, Takashi

AU - Narita, Nobuhiro

AU - Sawaki, Masayoshi

AU - Mikasa, Keiichi

AU - Soejima, Rinzo

AU - Niki, Yoshihito

AU - Sasaki, Takao

AU - Matsumoto, Yukio

AU - Sugimoto, Yuji

AU - Sawae, Yoshiro

AU - Ishimaru, Toshiyuki

AU - Takagi, Koji

AU - Yamane, Takayoshi

AU - Hayashida, Kazuhiro

AU - Kumagaya, Yukio

AU - Fukuma, Michio

AU - Murata, Hiroshi

AU - Gondo, Hideyuki

AU - Takii, Masahide

AU - Nasu, Masaru

AU - Shigeno, Hideaki

AU - Goto, Jun

AU - Tashiro, Takayoshi

AU - Hara, Kohei

AU - Kohno, Shigeru

AU - Hayashi, Toshiaki

AU - Kaku, Mitsuo

AU - Sasayama, Kazuo

AU - Yasuoka, Akira

AU - Izumikawa, Kinichi

AU - Watanabe, Kohichi

AU - Okuno, Kazuhiro

AU - Kohno, Kohta

AU - Ito, Naomi

AU - Iwasaki, Hiromaru

AU - Oda, Hiroshige

AU - Matsumoto, Keizo

AU - Nagatake, Tsuyoshi

AU - Yoshida, Toshiaki

AU - Ando, Masayuki

AU - Suga, Moritaka

AU - Yamaguchi, Keizo

AU - Sugawara, Kazuyuki

AU - Ggawa, Nobuya

PY - 1989

Y1 - 1989

N2 - Using the double-blind method, we evaluated the efficacy, safety and usefulness of cefotiam hexetil (CTM-HE) for the treatment of chronic respiratory tract infections using cefaclor (CCL) as control drug. The results obtained were as follows: Patients were given orally, in 3 divided doses, CTM-HE in a daily dose of 1200mg (as cefotiam) or CCL in a daily dose of 1500 mg for 14 consecutive days as a rule. 1) Clinical response was judged by the committee as good and excellent in 67. 3%(76/113) of thepatients on CTM-HE treatment and 65.2%(73/112) of those on CCL treatment, and by the attending physicians in 67.0%(75/112) of those on CTM-HE and 59. 8%(67/112) of those on CCL. 2) Bacteriological response by causative organisms was judged as eradicated in 64.0%(48/75) in the CTM-HE treatment group and 55.8%(43/77) in the CCL treatment group. 3) As for the safety evaluation, adverse reactions were reported in 7.6%(9/119) of the patients on CTM-HE and 8.8%(11/125) of those on CCL. Abnormal alterations of laboratory findings occured in 21.4%(24/112) of the patients on CTM-HE and 13.3%(15/113) of those on CCL. Major adverse reactions to both treatments included gastrointestinal disorders such as diarrhea. Most of the abnormal laboratory findings were increase in eosinophils and in serum transaminases, which did not particularly differ from those observed with conventionally available cephem antibiotics. 4) As to utility, the drug was judged as fairly useful and better by the committee in 66.4%(75/113) of the patients on CTM-HE and 62.6%(72/115) of those on CCL, and by the attending physicians in 65.2%(73/112) of those on CTM-HE and 59.1%(68/115) of those on CCL. The above results indicate that the daily dose of 1200 mg of CTM-HE is comparable to 1500 mg of CCL in efficacy and safety, and we conclude that CTM-HE is useful for the treatment of chronic respiratory tract infections.

AB - Using the double-blind method, we evaluated the efficacy, safety and usefulness of cefotiam hexetil (CTM-HE) for the treatment of chronic respiratory tract infections using cefaclor (CCL) as control drug. The results obtained were as follows: Patients were given orally, in 3 divided doses, CTM-HE in a daily dose of 1200mg (as cefotiam) or CCL in a daily dose of 1500 mg for 14 consecutive days as a rule. 1) Clinical response was judged by the committee as good and excellent in 67. 3%(76/113) of thepatients on CTM-HE treatment and 65.2%(73/112) of those on CCL treatment, and by the attending physicians in 67.0%(75/112) of those on CTM-HE and 59. 8%(67/112) of those on CCL. 2) Bacteriological response by causative organisms was judged as eradicated in 64.0%(48/75) in the CTM-HE treatment group and 55.8%(43/77) in the CCL treatment group. 3) As for the safety evaluation, adverse reactions were reported in 7.6%(9/119) of the patients on CTM-HE and 8.8%(11/125) of those on CCL. Abnormal alterations of laboratory findings occured in 21.4%(24/112) of the patients on CTM-HE and 13.3%(15/113) of those on CCL. Major adverse reactions to both treatments included gastrointestinal disorders such as diarrhea. Most of the abnormal laboratory findings were increase in eosinophils and in serum transaminases, which did not particularly differ from those observed with conventionally available cephem antibiotics. 4) As to utility, the drug was judged as fairly useful and better by the committee in 66.4%(75/113) of the patients on CTM-HE and 62.6%(72/115) of those on CCL, and by the attending physicians in 65.2%(73/112) of those on CTM-HE and 59.1%(68/115) of those on CCL. The above results indicate that the daily dose of 1200 mg of CTM-HE is comparable to 1500 mg of CCL in efficacy and safety, and we conclude that CTM-HE is useful for the treatment of chronic respiratory tract infections.

UR - http://www.scopus.com/inward/record.url?scp=0024344237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024344237&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.37.455

DO - 10.11250/chemotherapy1953.37.455

M3 - Article

AN - SCOPUS:0024344237

VL - 37

SP - 455

EP - 481

JO - CHEMOTHERAPY

JF - CHEMOTHERAPY

SN - 0009-3165

IS - 4

ER -